Journal article

Heritability and reliability of automatically segmented human hippocampal formation subregions

Christopher D Whelan, Derrek P Hibar, Laura S van Velzen, Anthony S Zannas, Tania Carrillo-Roa, Katie McMahon, Gautam Prasad, Sinead Kelly, Joshua Faskowitz, Greig deZubiracay, Juan E Iglesias, Theo GM van Erp, Thomas Frodl, Nicholas G Martin, Margaret J Wright, Neda Jahanshad, Lianne Schmaal, Philipp G Saemann, Paul M Thompson

NeuroImage | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2016

Grants

Awarded by Consortium grant from the NIH


Awarded by European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant


Awarded by Spanish Ministry of Economy and Competitiveness grant


Awarded by Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)


Awarded by DOD ADNI (Department of Defense)


Awarded by NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING


Awarded by NATIONAL INSTITUTE ON AGING


Funding Acknowledgements

This work was supported in part by a Consortium grant (U54 EB020403) from the NIH contributing to the Big Data to Knowledge (BD2K) Initiative, including the NIBIB.The study also received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 654911 (project "THALAMODEL"). Juan Eugenio Iglesias also acknowledges financial support from the Gipuzkoako Foru Aldundia (Fellows Gipuzkoa Program) and the Spanish Ministry of Economy and Competitiveness grant TEC2014-51882-P.Data collection and sharing for this project was funded in part by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.